research: combination treatment shows positive results compared to single agent
Posted Dec 09 2011 1:31am
Today’s topics at the San Antonio Breast Cancer Symposium 2011 included a presentation by principal investigator Gabriel Hortobagyi, MD, from MD Anderson, Department of Breast Medical Oncology.
Treatment for metastatic breast cancer may be undergoing a transition from single agents to combinations. A Phase III study, known as BOLERO-2, has shown positive results favoring the combination of everolimus and exemestane with an increase in progression-free survival from 3.2 months to 7.4 months over treatment with exemestane alone. Everolimus is classified as an immunosuppresant with antiangiogenic properties, and exemstane is an aromatase inhibitor. Study participants reported side effects that were tolerable, including shortness of breath, hyperglycemia, mouth sores and fatigue.
Today’s topics at the San Antonio Breast Cancer Symposium 2011 included a presentation by principal investigator Gabriel Hortobagyi, MD, from MD Anderson, Department of Breast Medical Oncology.
Treatment for metastatic breast cancer may be undergoing a transition from single agents to combinations. A Phase III study, known as BOLERO-2, has shown positive results favoring the combination of everolimus and exemestane with an increase in progression-free survival from 3.2 months to 7.4 months over treatment with exemestane alone. Everolimus is classified as an immunosuppresant with antiangiogenic properties, and exemstane is an aromatase inhibitor. Study participants reported side effects that were tolerable, including shortness of breath, hyperglycemia, mouth sores and fatigue.
University of Texas M. D. Anderson Cancer Center. Combination Of Everolimus And Exemestane Improves Progression-Free Survival For Women With Metastatic Breast Cancer. In Medical News Today. MediLexicon, Intl., 8 Dec. 2011. Web. 8 Dec. 2011.
5 6 7 8
© 2004–2011 Donna Peach. All rights reserved.